# Escitalopram versus placebo bij depressie na ACS en langetermijn cardiale uitkomsten: JAMA

*geplaatst 2018-07-24 · Algemeen · JAMA · doi 10.1001/jama.2018.9422 · https://hartvaat.nl/2018/07/24/escitalopram-versus-placebo-bij-depressie-na-acs-en-langetermijn-cardiale-uitkom/*

JAMA-trial naar het langetermijneffect van escitaloprambehandeling voor depressie na ACS op cardiale uitkomsten. Onderzoekt de psychocardiale interactie.

## English: Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.

This JAMA follow-up of escitalopram treatment for depression after ACS examined whether antidepressant therapy improves long-term cardiac outcomes, addressing the cardiovascular implications of treating comorbid depression in coronary patients.

## Abstract (original, from the publication)

IMPORTANCE: Depression has been associated with poorer medical outcomes in acute coronary syndrome (ACS), but there are few data on the effects of antidepressant treatment on long-term prognosis. OBJECTIVE: To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted among 300 patients with recent ACS and depression enrolled from May 2007 to March 2013, with follow-up completed in June 2017, at Chonnam National University Hospital, Gwangju, South Korea. INTERVENTIONS: Patients were randomly assigned to receive either escitalopram in flexible dosages of 5, 10, 15, or 20 mg/d (n = 149) or matched placebo (n = 151) for 24 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was MACE, a composite of all-cause mortality, myocardial infarction (MI), and percutaneous coronary intervention (PCI). Four secondary outcomes were the individual MACE components of all-cause mortality, cardiac death, MI, and PCI. Cox proportional hazards models were used to compare the escitalopram and placebo groups by time to first MACE. RESULTS: Among 300 randomized patients (mean age, 60 years; 119 women [39.3%]), 100% completed a median of 8.1 (interquartile range, 7.5-9.0) years of follow-up. MACE occurred in 61 patients (40.9%) receiving escitalopram and in 81 (53.6%) receiving placebo (hazard ratio [HR], 0.69; 95% CI, 0.49-0.96; P = .03). Comparing individual MACE outcomes between the escitalopram and placebo groups, respectively, incidences for all-cause mortality were 20.8% vs 24.5% (HR, 0.82; 95% CI, 0.51-1.33; P = .43), for cardiac death, 10.7% vs 13.2% (HR, 0.79; 95% CI, 0.41-1.52; P = .48); for MI, 8.7% vs 15.2% (HR, 0.54; 95% CI, 0.27-0.96; P = .04), and for PCI, 12.8% vs 19.9% (HR, 0.58; 95% CI, 0.33-1.04; P = .07). CONCLUSIONS AND RELEVANCE: Among patients with depression following recent acute coronary syndrome, 24-week treatment with escitalopram compared with placebo resulted in a lower risk of major adverse cardiac events after a median of 8.1 years. Further research is needed to assess the generalizability of these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00419471.

Auteurs: Jae-Min Kim, Robert Stewart, Yong-Seong Lee, Hee-Joon Lee, Min Chul Kim, Ju-Wan Kim, Hee-Ju Kang, Kyung-Yeol Bae, Sung-Wan Kim, Il-Seon Shin, Young Joon Hong, Ju Han Kim, Youngkeun Ahn, Myung Ho Jeong, Jin-Sang Yoon

---
Bron: JAMA, https://doi.org/10.1001/jama.2018.9422. Bijgewerkt 2026-07-03T13:26:37Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.